Abstracts tagged "Inflammation"

Abstract Number: 1603 • ACR Convergence 2023
Infection-Associated Antiphospholipid Antibodies and Their Potential Role in Sepsis Outcomes
Katarina Kmetova, Emily Chong, NaveenKumar K. Somanathapura, Sherwin Navaz, Lyndsay Kluge, Srilakshmi Yalavarthi, Jason Knight, Michael Maile and Yu Zuo, University of Michigan, Ann Arbor, MI
Background/Purpose: Antiphospholipid syndrome (APS) is an acquired autoimmune thrombophilia characterized by circulating antiphospholipid antibodies (aPL). While the association between aPL and infection has long been…
Abstract Number: 1749 • ACR Convergence 2023
Fatty Acid Synthase Is a Critical Repressor of Ferroptosis in Rheumatoid Arthritis
Qi Cheng, Mo chen, Xin chen, Yifan Xie, Yan Du and Huaxiang wu, The Second Affiliated Hospital Of Zhejiang University School Of Medicine, Hangzhou, China
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease with synovial inflammation as the main pathological feature, and can eventually lead to irreversible joint or…
Abstract Number: 1962 • ACR Convergence 2023
Toll-Like Receptor 7/8 Activation of Immune and Non-Immune Cells in Muscle by RNA-Containing Immune Complexes Can Contribute to Inflammation and the Pathogenesis of Myositis
Yin Wu¹, Aditee Deshpande¹, Nicholas Geraci¹, Vera Sellers², Phanindra Velisetty², David Fiorentino³, Kavita Y. Sarin³ and Andrew Bender¹, ¹Research Unit – Neurology and Immunology, EMD Serono, Billerica, MA, ²Discovery Technologies, EMD Serono, Billerica, MA, ³Department of Dermatology, Stanford University, Redwood City, CA
Background/Purpose: Tissue inflammation is a major disease driver in idiopathic inflammatory myopathies (IIM), leading to muscle weakness and, in the case of dermatomyositis (DM), a…
Abstract Number: 2445 • ACR Convergence 2023
Targeting of Endothelial Dysfunction in Lupus Nephritis: Effect on Human Renal Endothelial Cell Gene Expression and Outcomes in Murine Lupus Nephritis
Dayvia Russell¹, Sandra Sanchez², Evelyn Bruner² and Jim Oates², ¹Ralph H. Johnson VA Medical Center, Charleston, SC, ²Medical University of South Carolina, Charleston, SC
Background/Purpose: Lupus nephritis (LN) constitutes one of the most severe manifestations of systemic lupus erythematosus (SLE). Evidence points to endothelial nitric oxide synthase (eNOS) uncoupling,…
Abstract Number: 0061 • ACR Convergence 2023
Discovery of a RIPK2 Scaffolding Inhibitor for the Treatment of Joint Autoimmune Diseases
Marta Wlodarska¹, Chad Van Huis², Florian Hoss³, Rosana Meyer¹, Xiaokang Lu², Dominik Koelmel², Brian Sanchez², Chuck Lesch², Alissa Telling², Martin Minns¹, Nneka Mbah², Isabelle Lacan¹, Robert Aversa¹, Charles Lesburg¹, Carmen Yu², Stephen Soisson¹, Natalie Dales¹, Darryl Patrick¹, Anthony Opipari², Shifeng Pan⁴ and Luigi Franchi², ¹Odyssey Therapeutics, Boston, MA, ²Odyssey Therapeutics, Ann Arbor, MI, ³Odyssey Therapeutics, Frankfurt, Germany, ⁴Odyssey Therapeutics, San Diego, CA
Background/Purpose: Receptor interacting protein kinase 2 (RIPK2) is a key signaling node for inflammation caused by peptidoglycan (PGN). In the intestine, RIPK2 integrates signaling originating…
Abstract Number: 0418 • ACR Convergence 2023
Synovial Fluid Cell Counts Associated with Joint Histopathology in Rheumatoid Arthritis
Edoardo Spolaore¹, Edward DiCarlo², Daniel Ramirez², Melanie Smith², Amit Lakhanpal², Bella Mehta³, Laura Donlin², Susan Goodman² and Dana Orange⁴, ¹HSS, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴The Rockefeller University, New York, NY
Background/Purpose: While analysis of synovial fluid white blood cell counts (WBCs) is performed in clinical practice for diagnosing septic arthritis and differentiating noninflammatory from inflammatory…
Abstract Number: 0875 • ACR Convergence 2023
INV-1498, a Promising Caspase Inhibitor, Exhibits Dose-dependent Therapeutic Efficacy in a Canine Model of Osteoarthritis
Jung Gyu Park¹, Yurim Lee¹, Joonghoon Park² and myungjin Kim³, ¹Innovo Therapeutics Inc., Daejeon, South Korea, ²Institute of Green Bio Science and Technology, Seoul National University, Pyeongchang, South Korea, ³HLB bioStep Co. Ltd, Incheon, South Korea
Background/Purpose: Osteoarthritis poses a substantial medical challenge, as the available treatments primarily target symptom relief and fail to effectively halt the progressive cartilage deterioration that…
Abstract Number: 1101 • ACR Convergence 2023
Systemic Inflammation Associated with Silent Deposition of Monosodium Urate Crystals in Asymptomatic Hyperuricemia
Maria-Luisa Peral-Garrido¹, Paula Boix-Navarro², Silvia Gómez-Sabater³, Rocío Caño-Alameda³, Alejandra Bermúdez-García⁴, Teresa Lozano⁴, Ruth Sanchez-Ortiga⁴, Miguel Perdiguero⁴, Elena Caro-Martínez⁵, Carolina Ruiz-García⁶, Eliseo Pascual⁴, Rubén Francés² and Mariano Andrés⁴, ¹Vinalopó University Hospital, Novelda, Spain, ²Miguel Hernandez University, San Juan de Alicante, Spain, ³Rheumatology Department, Dr. Balmis University General Hospital, Alicante. Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain, ⁴Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, ⁵San Vicente Hospital-HACLE, San Vicente del Raspeig, Spain, ⁶Campoamor Health Centre, Alicante, Spain
Background/Purpose: Whether the presence of subclinical monosodium urate (MSU) crystal deposition leads to a pro-inflammatory state in asymptomatic hyperuricemia (AH) is unknown. We aimed to…
Abstract Number: 1630 • ACR Convergence 2023
Patient-Reported Fatigue Associated with Joint Histopathology in Rheumatoid Arthritis
Diyu Fisher¹, Dana Orange², Melanie Smith³, Bella Mehta⁴, Edoardo Spolaore⁵, Edward DiCarlo³, Dongmei Sun³, Laura Donlin³ and Susan Goodman³, ¹Stony Brook Medicine, Port Jefferson Station, NY, ²The Rockefeller University, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁵HSS, New York, NY
Background/Purpose: Fatigue or tiredness is an important symptom for patients with rheumatoid arthritis (RA), yet the factors associated with fatigue are poorly understood and may…
Abstract Number: 1750 • ACR Convergence 2023
Dysregulated NUB1 and Neddylation Enhances Rheumatoid Arthritis Fibroblast-Like Synoviocyte Inflammatory Responses
Sho Sendo¹, Camilla R. L. Machado², Robert Benschop³, Narayanan B. Perumal⁴, Eunice Choi⁵, David Boyle⁵, Wei Wang⁵ and Gary Firestein², ¹Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²University of California San Diego, San Diego, CA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Eli Lilly and Company, San Diego, CA, ⁵University of California San Diego, La Jolla, CA
Background/Purpose: Fibroblast-like synoviocytes (FLS) contribute to the pathogenesis of rheumatoid arthritis (RA), especially cartilage damage and cytokine production. These cells display an aggressive phenotype in…
Abstract Number: 2015 • ACR Convergence 2023
Synergistic Effect Between Denosumab and Immune Checkpoint Inhibitors : A Retrospective Study of 268 Patients with Bone Metastases
Emmanuel Massy¹, Etienne Mabrut¹, Sabine Mainbourg² and Cyrille Confavreux¹, ¹Centre Expert des Métastases Osseuses (CEMOS) - Service de Rhumatologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Université de Lyon, INSERM UMR 1033-LYOS, Lyon, France, ²Service de médecine interne et vasculaire, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, F-69495 Pierre-Bénite, Laboratoire de Biométrie et Biologie Evolutive, Université Lyon 1; CNRS, UMR 5558, 69622 Villeurbanne, Lyon, France
Background/Purpose: Bone is the third site of metastasis. Bone metastases are associated with poorer survival of patients and impaired quality of life with the occurrence…
Abstract Number: 2496 • ACR Convergence 2023
HXB-319, a New Generation Mesenchymal Stromal Cell (MSC) Therapy, Alleviates Neutrophilic Inflammation, and End-organ Damage in Pulmonary Renal Syndromes by Inducing FoxP3+ Tregs, and by Promoting TNFα-stimulated gene-6 (TSG-6) over Expression
Hulya Bukulmez¹, Adrienne Dennis¹, Jane Reese-Koc², Scott Sieg² and Steven Emancipator², ¹MetroHealth Medical Center, Department of Pediatrics, Cleveland, OH, ²Case Western Reserve University, Cleveland, OH
Background/Purpose: Mesenchymal stromal cells (MSCs) have been shown to be safe therapies in more than 100 human clinical trials. However, MSCs clinical efficacy is variable,…
Abstract Number: 0067 • ACR Convergence 2023
Dimethyl Fumarate Modulates T Cell Metabolism and Function in Systemic Lupus Erythematosus Patient Samples
Loren Kell¹, Samuel Taylor², Kavina Shah², Roel De Maeyer², Debajit Sen², Madhura Castelino², Jo Cambridge², David Isenberg², Maria Leandro³, Arne Akbar² and venkat Reddy², ¹University College London, Oxford, United Kingdom, ²University College London, London, United Kingdom, ³University College London/UCLH, London, United Kingdom
Background/Purpose: Activated T cells make a significant contribution to inflammation in systemic lupus erythematosus (SLE). We know that cellular metabolism regulates the activation of T…
Abstract Number: 0427 • ACR Convergence 2023
Molecular Characterization of Biologic and Targeted Synthetic DMARDs Effects Through Ex- vivo Studies in Rheumatoid Arthritis Immune Cells
Laura Muñoz-Barrera¹, Carlos Perez-Sanchez², Laura Romero-Zurita¹, Rafaela Ortega Castro³, Jerusalem Calvo⁴, Pilar Font Ugalde¹, Marta Rojas⁵, Ismael Sanchez-Pareja¹, Maria del Carmen Abalos-Aguilera⁶, Desiree Ruiz-Vilchez¹, Christian Merlo-Ruiz¹, Mª Angeles Aguirre⁷, Nuria Barbarroja⁸, Tomás Cerdó¹, Eduardo Collantes Estévez⁹, Marta Alarcon-Riquelme¹⁰, Alejandro Escudero Contreras⁴ and Chary Lopez-Pedrera¹¹, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ²IMIBIC, Córdoba, Spain, ³Hospital Reina Sofía, Cordoba, Spain, ⁴Reina Sofia University Hospital, Córdoba, Spain, ⁵Hospital Universitario Reina Sofía, Cordoba, Spain, ⁶Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, ⁷Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, ⁸University of Cordoba, Córdoba, Spain, ⁹Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Cordoba, Spain, ¹⁰Center for Genomics and Oncological Research (GENYO), Granada, Spain, ¹¹IMIBIC - Reina Sofia Hospital, Córdoba, Spain
Background/Purpose: Despite advances in rheumatoid arthritis (RA) treatment, a significant proportion of patients (10-30%) fail to respond to current medications, including biologics. A better characterization…
Abstract Number: 0880 • ACR Convergence 2023
CD14 Inhibition as a Potential Therapeutic in Post Traumatic OA
Kevin Burt¹, Vu Nguyen¹, Lance Murphy², De'Broski Herbert¹, Robert Mauck¹ and Carla Scanzello³, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ³Translational Musculoskeletal Research Center, Corp. Michael J Crescenz VA Medical Center,4Division of Rheumatology, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA
Background/Purpose: Osteoarthritis (OA) is the most common joint disorder, and growing evidence has identified inflammation to be a major driver of disease progression. During disease,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].